in cases with risk factors, comorbidities and/or concomitant medications where GC-related adverse events are more likely to occur. MTX may also be considered during follow-up in patients with a relapse, without a significant response to GC or experiencing GC-related adverse events. In clinical trials, MTX has been used at oral doses of 7.5-10 mg/week Similar to the explanation of Recommendation 5, the panel felt that there is no clinical prototype unconditionally warranting treatment with MTX,